Denise Yardley, MD, discusses challenges with resistance mechanisms in hormone receptor–positive, HER2-negative breast cancer.
Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses challenges with resistance mechanisms in hormone receptor (HR)–positive, HER2-negative breast cancer.
Resistance to CDK4/6 inhibitors remains a significant challenge in HR-positive, HER2-negative breast cancer, says Yardley. Learning how to characterize and predict resistance early on is of critical importance.
Notably, several ongoing studies are trying to identify sensitivity and resistance biomarkers, Yardley says. However, estrogen receptor positivity remains the most established biomarker for benefit.
In addition, the field is looking for ways to identify patients who may have intrinsic resistance, resistance after 6 months, or acquired resistance through Rb, PI3K, and cyclin E, Yardley concludes.